Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Cellyan Biotechnology Co's retained earnings for the quarter that ended in Sep. 2025 was $1.66 Mil.
Cellyan Biotechnology Co's quarterly retained earnings
declined
from Sep. 2024 ($2.36 Mil) to Mar. 2025 ($1.50 Mil) but then
increased
from Mar. 2025 ($1.50 Mil) to Sep. 2025 ($1.66 Mil).
Cellyan Biotechnology Co's annual retained earnings
increased
from Mar. 2023 ($0.20 Mil) to Mar. 2024 ($1.53 Mil) but then
declined
from Mar. 2024 ($1.53 Mil) to Mar. 2025 ($1.50 Mil).
Cellyan Biotechnology Co (NAS:HKPD) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Cellyan Biotechnology Co Retained Earnings Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co Retained Earnings Calculation
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Cellyan Biotechnology Co (HKPD) has a Retained Earnings of $1.66 Mil as of Sep. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Cellyan Biotechnology Co and its competitors.
Is Cellyan Biotechnology Co's Retained Earnings too high?
Cellyan Biotechnology Co's current Retained Earnings is $1.66 Mil. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Retained Earnings compare to COSM and SNYR?
Cellyan Biotechnology Co's Retained Earnings of $1.66 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Distribution company?
A good Retained Earnings depends on the Medical Distribution industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Cellyan Biotechnology Co and its competitors. Cellyan Biotechnology Co's current Retained Earnings is $1.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Retained Earnings of $1.66 Mil. The current Retained Earnings is $1.66 Mil. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Retained Earnings is $1.66 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score
Get the complete analysis for HKPD
Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
